Advertisement

Emerging Immunologic Approaches, to Treatment of Neoplastic Diseases

  • L. Olsson
  • G. Mathé
Part of the Recent Results in Cancer Research book series (RECENTCANCER, volume 80)

Summary

Recent research on the immunobiology of the tumor-host relationship has demonstrated that nonspecific cellular immune reactions, like natural killer cells and cytotoxic autoreactive cells, may be far more potent antineoplastic mechanisms than specific T lymphocyte cytotoxicity. The hybridoma technique, making it possible to raise monoclonal antibodies against predefined antigens, has rendered passive immunotherapy more attractive. It is suggested that the combination of nonspecific cellular immune reactions with monoclonal antibodies may be a highly efficient antineoplastic therapy for minimal residual disease.

Keywords

Natural Killer Cell Minimal Residual Disease Spontaneous Tumor Human Malignant Tumor Passive Immunotherapy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Burnet FM (1970) The concept of immunological surveillance. Prog Exp Tumor Res 13:1–27PubMedGoogle Scholar
  2. 2.
    Cerottini JC, Brunner KT (1974) Cell-mediated cytotoxicity, allograft rejection, and tumor immunity. Adv Immunol 18:67–132PubMedCrossRefGoogle Scholar
  3. 3.
    Ehrlich P (1909) Über den jetzigen Stand der Karzinomforschung. Ned Tijds Chr Geneeskd 1:273–290Google Scholar
  4. 4.
    Foley EJ (1953) Antigenic properties of methylcholanthrene-induced tumors in mice of the strain of origin. Cancer Res 13:835–837PubMedGoogle Scholar
  5. 5.
    Herberman R, Holden HT (1978) Natural cell-mediated immunity. Adv Cancer Res 27:305–377PubMedCrossRefGoogle Scholar
  6. 6.
    Hewitt HB (1978) The choice of animal tumors for experimental studies of cancer therapy. Adv Cancer Res 27:149–200PubMedCrossRefGoogle Scholar
  7. 7.
    Hulett HR, Bonner WA, Barrett J, Herzenberg LA (1969) Cell sorting: Automated separation of mammalian cells as a function of intracellular fluorescence. Science 166:747–749Google Scholar
  8. 8.
    Klein G (1980) Immune and non-immune control of neoplastic development. Contrasting effects of host and tumor evolution. Cancer 45:2486–2499PubMedCrossRefGoogle Scholar
  9. 9.
    Klein G, Klein E (1979) Immune surveillance against virus-induced tumors and non-rejectability of spontaneous tumors: Contrasting consequences of host-versus-evolution. Proc Natl Acad Sei 74:2121–2125Google Scholar
  10. 10.
    Klein G, Sjögren HO, Klein E, Hellström KE (1960) Demonstration of resistance against methylcholanthrene-induced sarcomas in the primary autochthnous host. Cancer Res 20:1561–1572PubMedGoogle Scholar
  11. 11.
    Klein E, Masucci MG, Masucci G, Vauley F (to be published) Natural and activated lymphocyte killers, which affect tumor cells. In: Natural cell-mediated immunity against tumors. Academic Press, New YorkGoogle Scholar
  12. 12.
    Köhler G, Milstein C (1975) Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256:495–497PubMedCrossRefGoogle Scholar
  13. 13.
    Law LW (1970) Studies of tumour antigens and tumour specific immune mechanisms in experimental systems. Transpl Proc 2:117–132Google Scholar
  14. 14.
    Melcher F, Potter M, Warner N (1978) Lymphocyte hybridomas. Mod Top Immunol Microbiol 81:1–246Google Scholar
  15. 15.
    Olsson L (to be published) Immunity and malignant tumors. Cancer Biol RevGoogle Scholar
  16. 16.
    Olsson L, Ebbesen P (1979) Natural polyclonality of spontaneous AKR leukemia and its impact on so-called specific immunotherapy. J Natl Cancer Inst 62:623–627PubMedGoogle Scholar
  17. 17.
    Prehn RT, Main JM (1957) Immunity to methylcholanthrene-induced sarcomas. J Natl Cancer Inst 18:769–778PubMedGoogle Scholar
  18. 18.
    Sjögren HO (1965) Transplantation methods as a tool for detection of tumor-specific antigens. Prog Exp Tumor Res 6:289–322PubMedGoogle Scholar
  19. 19.
    Thomas L (1959) Discussion. In: Lawrence HS (ed) Cellular aspects of the hypersensitive state. Hoeber, New York, p 530Google Scholar

Copyright information

© Springer-Verlag Berlin · Heidelberg 1982

Authors and Affiliations

  • L. Olsson
    • 1
  • G. Mathé
    • 1
  1. 1.Institut of Cancerology and Immunogenetics, (INSERM U-50)Hôpital Paul-BrousseVillejuifFrance

Personalised recommendations